Species |
Human |
Protein Construction |
Coagulation factor XI (Glu19-Val625) Accession # P03951-1 |
His |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Coagulation factor XI, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiFactor XI Antibody, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
69.1 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII.In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis. |
Synonyms |
Coagulation factor XI; FXI; PTA; F11; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.